Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeEXECUTIVESProf. Dr. Ricky Sharma is Appointed Varian VP of of Clinical Affairs

Prof. Dr. Ricky Sharma is Appointed Varian VP of of Clinical Affairs

Dr. Ricky Sharma has been appointed vice president of clinical affairs at Varian.

In this role, Dr. Ricky Sharma will be leading medical research, translational science and clinical trials for Varian’s growing oncology business. Dr. Ricky Sharma will report directly to Dee Khuntia, MD, chief medical officer and senior vice president of Medical Affairs.

A pioneer in internal radiotherapy and chemotherapy treatments for patients with liver metastases, he transformed liver cancer care by providing evidence-based data to drive cancer treatment options. Dr. Sharma’s vision of multidisciplinary care includes combining radiation therapies, physical therapies (thermal ablation, cryotherapy, embolics), and pharmacologic tools (drug-eluting beads, immunological agents, chemotherapeutic agents) to deliver personalized care for every patient.

Dr. Sharma has personally served as the global chief investigator in 15 phase I, II or III clinical trials in the fields of radiation, medical and interventional oncology, including multi-center, pivotal randomized controlled trials testing new drug-radiotherapy combinations which have enrolled over 2,000 cancer patients. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists and he has published over 200 articles in scientific journals.

Prior to joining Varian, Dr. Sharma was the Chair of Radiation Oncology at University College London, UK, where he will continue as an honorary clinical professor. He is also a visiting professor at several universities in other countries.

“Dr. Sharma is an international authority on the multi-modality treatment of cancer with precision radiotherapy as well as on the translation of radiobiology from the laboratory to the clinic,” said Dr. Khuntia. “His experience of leading practice-changing international clinical trials and his well-established track record in taking cancer care innovations from the scientific laboratory to patients in the clinic will be critical in demonstrating a strong evidence base for Varian’s new technologies in the fight against cancer.”

“It is an honor to join Varian to spearhead its ongoing efforts to provide the best treatment to patients anywhere in the world,” said Prof. Dr. Sharma. “I am proud to be part of a company that innovates, supports and simplifies cancer-fighting solutions everywhere to create a world without fear of cancer.”

Dr. Sharma obtained his medical degree and an M.A. from the University of Cambridge, UK, and subsequently a PhD from the MRC Toxicology Unit, University of Leicester. Dr. Sharma was an Associate Professor at the University of Oxford, UK, where he was a consultant in Clinical Oncology.  He has a clinical practice in chemotherapy and radiotherapy, which he will continue.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy